Somatostatinoma: all 51 studies
Page 1 of 1. Open to participants first (2), then studies with results posted, then the rest; newest registration first within each.
- Association Between Health Care Provider (HCP)-Assessed ECOG Performance Status (PS) and Overall Survival, and Objectively Measure of Physical Activity (PA) Levels in Advance-cancer Patients"RecruitingNCT01365169Not applicable
- Collecting Medical Information and Tissue Samples From Patients With Pancreatic Cancer or Other Pancreatic DisordersRecruitingNCT00830557
- Liposomal Irinotecan, Fluorouracil and Leucovorin in Treating Patients With Refractory Advanced High Grade Neuroendocrine Cancer of Gastrointestinal, Unknown, or Pancreatic OriginTerminatedNCT03736720Phase 2Results posted
- Sapanisertib in Treating Patients With Metastatic or Refractory Pancreatic Neuroendocrine Tumor That Cannot Be Removed by SurgeryCompletedNCT02893930Phase 2Results posted
- Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced Poorly Differentiated (G3) Non-Small Cell Gastrointestinal Neuroendocrine CarcinomasActive, not recruitingNCT02595424Phase 2Results posted
- Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney CancerTerminatedNCT02273752Phase 2Results posted
- Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine TumorsCompletedNCT02259725Phase 2Results posted
- Ziv-Aflibercept in Treating and Computed Tomography Perfusion Imaging in Predicting Response in Patients With Pancreatic Neuroendocrine Tumors That Are Metastatic or Cannot Be Removed by SurgeryCompletedNCT02101918Phase 2Results posted
- Everolimus in Patients With Pancreatic Neuroendocrine Tumors Metastatic to the Liver Previously Treated With SurgeryTerminatedNCT02031536Phase 2Results posted
- Comparative Study of Sensitivity of Ga-DOTATOC PET vs Octreoscan SPECT + CTCompletedNCT01869725Phase 2Results posted
- Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine TumorsCompletedNCT01824875Phase 2Results posted
- Capecitabine, Temozolomide, and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine TumorsCompletedNCT01525082Phase 2Results posted
- Panobinostat & Bortezomib in Pancreatic Cancer Progressing on Gemcitabine TherapyTerminatedNCT01056601Phase 2Results posted
- Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell CancerCompletedNCT01010126Phase 2Results posted
- Capecitabine and Temozolomide for Neuroendocrine CancersCompletedNCT00869050Phase 2Results posted
- Doxorubicin Beads in Treating Patients With Unresectable Liver Metastases From Neuroendocrine TumorsTerminatedNCT00730483Not applicableResults posted
- Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer PainCompletedNCT00538850Phase 3Results posted
- Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine CancerCompletedNCT00454363Phase 2Results posted
- A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.CompletedNCT00428220Not applicableResults posted
- AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine TumorsCompletedNCT00427349Phase 2Results posted
- Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine TumorsTerminatedNCT00227617Phase 2/3Results posted
- Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine TumorsCompletedNCT00131911Phase 2Results posted
- Multicenter Trial of ESK981 in Patients With Select Solid TumorsActive, not recruitingNCT05988918Phase 2
- Assessment of What Patients and Healthcare Providers ValueCompletedNCT04483349
- Diagnosis of PCL With EUS-FNA and Cross-sectional Imaging - A Report of AccuracyStatus unknownNCT03884179
- Nivolumab and Ipilimumab in Treating Patients With Rare TumorsActive, not recruitingNCT02834013Phase 2
- Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine TumorWithdrawnNCT02831179Phase 1
- A Trial to Assess the Activity and Safety of Palbociclib in Patients With Well and Moderately Differentiated Metastatic Pancreatic Neuroendocrine Tumors (pNET)CompletedNCT02806648Phase 2
- Antitumor Efficacy of Peptide Receptor Radionuclide Therapy With 177Lutetium -Octreotate Randomized vs Sunitinib in Unresectable Progressive Well-differentiated Neuroendocrine Pancreatic Tumor: First Randomized Phase IICompletedNCT02230176Phase 2
- Dovitinib Lactate in Treating Patients With Pancreatic Neuroendocrine TumorsWithdrawnNCT02108782Phase 2
- Potential Molecular Predictors of Response to Novel Therapies in Metastatic Pancreatic Neuroendocrine TumorsCompletedNCT01603004
- Culture and Characterization of Circulating Tumor Cells (CTC) in Melanoma and Other CancersCompletedNCT01528774
- Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine CarcinomaCompletedNCT01204476Phase 1
- Everolimus and Vatalanib in Treating Patients With Advanced Solid TumorsCompletedNCT00655655Phase 1
- Capecitabine and Streptozocin With or Without Cisplatin in Treating Patients With Unresectable or Metastatic Neuroendocrine TumorsCompletedNCT00602082Phase 2
- Internal Radiation Therapy in Treating Patients With Liver Metastases From Neuroendocrine TumorsTerminatedNCT00466856Phase 2
- Disease-Specific Questionnaire in Assessing Quality of Life in Patients With Gastrointestinal-Related Neuroendocrine TumorsStatus unknownNCT00454376
- Safety and Efficacy Study of In-111 Pentetreotide to Treat Neuroendocrine TumorsCompletedNCT00442533Phase 2/3
- Combination Chemotherapy as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors of the Duodenum or Pancreas That Cannot Be Removed By SurgeryCompletedNCT00416767Phase 2
- Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine TumorsWithdrawnNCT00227773Phase 2
- Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver CancerCompletedNCT00096083Phase 2
- Romidepsin in Treating Patients With Locally Advanced or Metastatic Neuroendocrine TumorsTerminatedNCT00084461Phase 2
- Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine TumorsCompletedNCT00075439Phase 2
- Thalidomide in Treating Patients With Metastatic Neuroendocrine TumorsCompletedNCT00027638Phase 2
- PS-341 in Treating Patients With Metastatic Neuroendocrine TumorsCompletedNCT00017199Phase 2
- Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent CancerCompletedNCT00006368Phase 1
- Oxaliplatin With Or Without Floxuridine and Leucovorin in Treating Patients With Metastatic Cancer of the PeritoneumCompletedNCT00005860Phase 1
- Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic CancerCompletedNCT00005842Phase 1
- Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/NeuCompletedNCT00004074Phase 1
- Antineoplaston Therapy in Treating Patients With Neuroendocrine Tumor That Is Metastatic or Unlikely to Respond to Surgery or Radiation TherapyWithdrawnNCT00003514Phase 2
- Indium In 111 Pentetreotide in Treating Patients With Refractory CancerTerminatedNCT00002947Phase 1